Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
IO Biotech, Inc. IOBT
$2.07
-$0.04 (-2.01%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
58495059.00000000
-
week52high
7.79
-
week52low
1.72
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-2.47000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 04:00
Описание компании
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | 30 ноя 2021 г. | |
| Jefferies | Buy | 30 ноя 2021 г. | |
| Cowen & Co. | Outperform | 30 ноя 2021 г. | |
| HC Wainwright & Co. | Buy | 21 ноя 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Smith Devin Whittemore | A | 150000 | 150000 | 12 янв 2023 г. |
| Sullivan Amy | A | 288152 | 288152 | 17 окт 2022 г. |
| Burkavage Brian | A | 20000 | 20000 | 31 мая 2022 г. |
| Hirth Peter | A | 23885 | 23885 | 26 мая 2022 г. |
| Glaub Kathleen Sereda | A | 23885 | 23885 | 26 мая 2022 г. |
| Smith David V | A | 23885 | 23885 | 26 мая 2022 г. |
| Elling Christian E | A | 23885 | 23885 | 26 мая 2022 г. |
| Nielsen Jack | A | 23885 | 23885 | 26 мая 2022 г. |
| Smith David V | A | 28019 | 28019 | 01 мар 2022 г. |
| HBM Healthcare Investments (Cayman) Ltd. | D | 0 | 188168 | 09 ноя 2021 г. |
Новостная лента
IO Biotech to Present at 42nd Annual Cowen Healthcare Conference
GlobeNewsWire
04 мар 2022 г. в 08:00
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today it will present at the 42nd Annual Cowen Health Care Conference to be held virtually March 7 – 9, 2022. At the conference, IO Biotech CEO Dr. Mai-Britt Zocca will participate in the Novel IO Panel Discussion.
IO Biotech (IOBT) Stock: $21 Price Target From Morgan Stanley
Pulse2
03 дек 2021 г. в 10:55
The shares of IO Biotech Inc (NASDAQ: IOBT) have received a $21 price target from Morgan Stanley. These are the details.